物理化学学报
物理化學學報
물이화학학보
ACTA PHYSICO-CHIMICA SINICA
2012年
7期
1783-1789
,共7页
林克江%朱冬吉%冷勇敢%尤启冬
林剋江%硃鼕吉%冷勇敢%尤啟鼕
림극강%주동길%랭용감%우계동
甲状腺旁素1型受体%甲状腺旁素%同源模建%甲状腺旁素复合物
甲狀腺徬素1型受體%甲狀腺徬素%同源模建%甲狀腺徬素複閤物
갑상선방소1형수체%갑상선방소%동원모건%갑상선방소복합물
Parathyroid hormone 1 receptor%Parathyroid hormone%Homology modeling%PTH-PTH 1R complex
人甲状腺旁素1型受体(PTH1R)是骨形成相关的B类G蛋白偶联受体,其底物甲状腺旁腺素(PTH)及类似物具有抗骨质疏松作用,由于此类受体的三维结构难以进行实验测定,本文采用同源模建的方法,完整构建了胞外区、跨膜区及其它相关区域,并通过对接研究,阐明复合物的氢键、疏水性相互作用及其与底物的相互作用关系和关键位点.为进一步设计和发展此类药物提供理论依据.
人甲狀腺徬素1型受體(PTH1R)是骨形成相關的B類G蛋白偶聯受體,其底物甲狀腺徬腺素(PTH)及類似物具有抗骨質疏鬆作用,由于此類受體的三維結構難以進行實驗測定,本文採用同源模建的方法,完整構建瞭胞外區、跨膜區及其它相關區域,併通過對接研究,闡明複閤物的氫鍵、疏水性相互作用及其與底物的相互作用關繫和關鍵位點.為進一步設計和髮展此類藥物提供理論依據.
인갑상선방소1형수체(PTH1R)시골형성상관적B류G단백우련수체,기저물갑상선방선소(PTH)급유사물구유항골질소송작용,유우차류수체적삼유결구난이진행실험측정,본문채용동원모건적방법,완정구건료포외구、과막구급기타상관구역,병통과대접연구,천명복합물적경건、소수성상호작용급기여저물적상호작용관계화관건위점.위진일보설계화발전차류약물제공이론의거.
Parathyroid hormone 1 receptor (PTH1R) is a member of the class B G-protein coupled receptor (B-GPCR) family and is involved in bone formation.Its substrate parathyroid hormone (PTH) and its analogues are being developed as anti-osteoporosis therapeutics.The structure-based rational drug design of PTH1R substrates has been hampered by the lack of experimentally determined three-dimensional (3D) structures from techniques such as nuclear magnetic resonance (NMR) and X-ray crystallography.Here,we have constructed a 3D model of PTH1R including its extracellular domain (ECD),transmembrane (TM)domain,and other domains using a homology modeling approach.In addition,to capture the ligand-receptor interactions,we have manually docked human parathyroid hormone (1-34) into the top scoring receptor model,and subjected the PTH-PTH1R complex to an unconstrained energy minimization.The integral 3D receptor model provides an easier way to understand the interactions involved at the TM,ECD,and other domains.Furthermore,the parameters of hydrogen bonding,hydrophobic,and other interactions from the ligand-receptor model,enabled us to elucidate the important interactions between PTH (1-34) and PTH1R.This ligand-receptor model could potentially serve as a tool for structure-based virtual screening in the development of non-peptide based anti-osteoporosis drugs.